Volume 9, Issue 4 (2023)
Pharm Biomed Res 2023, 9(4): 259-266 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rasheed T O, Higazy W M N, Yisa Abiodun B. Diagnosis and Critique of Drugs Used in Treating Coronavirus Disease in 2019 in Nigeria: A Review. Pharm Biomed Res 2023; 9 (4) :259-266
URL: http://pbr.mazums.ac.ir/article-1-554-en.html
URL: http://pbr.mazums.ac.ir/article-1-554-en.html
1- Department of Health, Safety & Environment Studies, Training & Research Institute, Economic and Financial Crimes Commission Academy, Karu, Nigeria
2- Department of Pharmacy, EISAI Pharmaceuticals, Nutley, United States of America.
3- Department of Nursing, Lagos State College of Nursing, Igando, Nigeria.
2- Department of Pharmacy, EISAI Pharmaceuticals, Nutley, United States of America.
3- Department of Nursing, Lagos State College of Nursing, Igando, Nigeria.
Abstract: (1140 Views)
Background and Objectives: Drugs used in treating patients who contracted the coronavirus disease of 2019 (COVID-19) include chloroquine or hydroxychloroquine (CQ, HCQ), antiviral, steroid, and antibiotic. Treatment outcomes were characterized by positive and adverse reactions as therapeutic options were based on clinical trials coupled with diagnostic constraints. This study assesses the diagnostic processes and critically examines the drugs used in the clinical settings to treat COVID-19 in Nigeria.
Methods: The search was conducted on various databases with a focus on diagnoses and drugs used to treat COVID-19. Articles that did not meet selection criteria were excluded and the data collected from sampled articles were collated, analyzed, and evaluated.
Results: The finding showed a lack of sufficient evidence-based data to support the use of CQ/HCQ, remdesivir, lopinavir/ritonavir, and antibiotics, such as azithromycin as treatment options for COVID-19, even though patients responded partly to the drugs probably due to their action mechanisms.
Conclusion: There is a lack of evidence-based scientific data to guide the definitive treatment of COVID-19 patients during the pandemic. Drugs used in the emergency were based on clinical trials. The efficacy of the drugs depends partly on the innate capability of the immune system of an affected individual.
Methods: The search was conducted on various databases with a focus on diagnoses and drugs used to treat COVID-19. Articles that did not meet selection criteria were excluded and the data collected from sampled articles were collated, analyzed, and evaluated.
Results: The finding showed a lack of sufficient evidence-based data to support the use of CQ/HCQ, remdesivir, lopinavir/ritonavir, and antibiotics, such as azithromycin as treatment options for COVID-19, even though patients responded partly to the drugs probably due to their action mechanisms.
Conclusion: There is a lack of evidence-based scientific data to guide the definitive treatment of COVID-19 patients during the pandemic. Drugs used in the emergency were based on clinical trials. The efficacy of the drugs depends partly on the innate capability of the immune system of an affected individual.
Keywords: Anti-bacterial agents, Antiviral agents, COVID-19 diagnostic testing, COVID-19 drug treatment, Hydroxychloroquine, Nigeria
Type of Study: Review article |
Subject:
Drug Clinical Investigation
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
